• Patient must have histologically confirmed uterine cervical adenocarcinoma
• Patient must be suitable surgical candidate with preoperative assessments
  such as labs and EKG performed per institutional standard.
• Patient must have signed an approved informed consent and authorization
  permitting the release of personal health information.

• Patients with FIGO stage 1A1, IB3, II-IV (2018 staging).
• Patient with inability to receive an MRI.
• Patients with a tumor size greater than 4cm on MRI confirmed prior to
  randomization are excluded. Patients with definite evidence of
  vaginal/parametrial involvement on MRI are excluded; if MRI findings are not
  definitive, then clinical examination must also not reveal parametrial or
  vaginal extension.
• Patients with a history of prior pelvic or abdominal radiotherapy.

Open radical hysterectomy vs robotic radical hysterectomy

The patient will not be paid for taking part in this study. The patient and/or the patient’s insurance plan will be filed and held responsible for the medical care costs as you get as part of the study, just as you would if you were getting the usual care for your cancer.

To compare the 3-year disease-free survival for patients who undergo robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage uterine cervical cancer.